DFV890

Near Add Your Location

Accepting patients

DFV890

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Learn more
  • NLRP3 Inhibitor
  • Phase 1